According to the researchers, a common pain reliever is being tested as a potential treatment for coronavirus patients admitted to hospital to see if it reduces the risk of blood clots. Aspirin, a known blood thinner, will be provided to patients enrolled in the RESTORE trial in the UK, according to a newsletter.
The researchers plan to give aspirin to about 2,000 patients in the trial in addition to standard care treatment. Results will be compared with 2,000 patients who received only standard care and assessed mortality after 28 days, as well as the impact on length of hospital stay and need for mechanical ventilation.
“We feel that adding aspirin to the trial is particularly important because there is clear reason to believe it can be beneficial and safe, inexpensive and widely available,” said Peter Horby, professor at the Nuffield Faculty of Medicine and RECOVERY’s lead investigator associate, said in the newsletter. “We are looking for drugs for COVID-19 that can be used immediately for anyone, anywhere in the world. We don’t know if aspirin is such a drug, but we’ll find out. “
US TOPS 120,000 FIRST DAILY ERRORS
According to the FDA, when used daily, aspirin has been shown to reduce the risk of heart attack, blood clot-related stroke and other blood flow problems in patients with cardiovascular disease or who have had have a heart attack or stroke. It is also used as an analgesic and relieves fever or inflammation.
DOORS JOINT STOCK COMPANY HAS ARRIVED TO THE EARLY ELECTION WEBSITE IN NY
Other treatments currently being evaluated in the RESTORE trial include azithromycin, tocilizumab, nursing plasma and REGN-COV2, an investigative antiviral antibody mixture developed by Regeneron.
CLICK HERE TO COMPLETE CORONAVIRUS INSURANCE
Researchers expect results after a few months.